KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy KRRO?
Source: moomoo
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRRO
Wall Street analysts forecast KRRO stock price to rise
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 12.050
Low
7.00
Averages
25.75
High
81.00
Current: 12.050
Low
7.00
Averages
25.75
High
81.00
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
See More
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
See More
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
See More
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
See More
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
KORRO BIO INC Reports Quarterly EPS of $-1.69
- Financial Overview: The company reported a quarterly loss of $1.69 million.
- Market Impact: The financial results may influence investor confidence and stock performance.
- Future Projections: Analysts are closely monitoring upcoming strategies to improve profitability.
- Industry Context: The results reflect broader trends affecting the industry, including economic challenges.
See More
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- Revenue Report Overview: The report details the revenue generated by KORROBIO for the first quarter of 2026.
- Collaboration Status: There is no collaboration reported in the current revenue figures, indicating a focus on independent operations.
See More
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
- Funding Expectations: KORROBIO anticipates a cash position that will support its operations into the second half of 2028.
- Operational Strategy: The company is focusing on maintaining sufficient funds to ensure ongoing operational capabilities.
See More
Korro Bio Showcases RNA Editing Technology at Multiple International Conferences
- Conference Presentations: Korro Bio will present its GalNAc-conjugated oligonucleotide KRRO-121 at the 3rd International Conference on Ureagenesis Defects from April 22-24, 2026, showcasing its robust ammonia clearance in preclinical hyperammonemia models, highlighting its potential in treating rare diseases.
- ASGCT Participation: At the American Society of Gene and Cell Therapy Annual Meeting from May 11-15, 2026, Korro will discuss the effectiveness of its RNA editing oligonucleotide in restoring Alpha-1 Antitrypsin function in AATD models, demonstrating its application prospects in precision medicine.
- Technological Innovations: Korro's OPERA® platform will be featured at the TIDES USA conference from May 11-14, 2026, emphasizing its innovations in large-scale RNA editing that are crucial for generating drug candidates, potentially accelerating the development of new therapies.
- EASL Congress Involvement: At the EASL Congress from May 27-30, 2026, Korro will present research on the increased healthcare resource utilization associated with uncontrolled ammonia in hepatic encephalopathy, further underscoring its contributions to liver disease research.
See More
"Q1's 5 Major Insider Purchases: Should You Buy, Sell, or Hold in Q2?"
Insider Buying Trends: In Q1 2026, insiders showed strong confidence by purchasing stocks, particularly in E.W. Scripps, which had the most insider buying activity, indicating a positive outlook for the company's performance.
Institutional Support: Institutions are also actively buying stocks, owning nearly 70% of E.W. Scripps, which provides a solid support base, while analysts remain cautious with mixed ratings and sentiment.
Market Sentiment and Analyst Ratings: Despite increased coverage and a generally firm sentiment, analysts have mixed reviews, with some rating stocks as a hold, while others see potential upside, particularly in sectors like service property trusts.
Catalysts for Growth: Key catalysts for growth in various stocks include international expansion, improvements in cash flow, and advancements in technology, which could enhance performance as the year progresses.
See More
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
